Future Science Group
Supplementary materials (5).docx (30.83 kB)

UK Cost-Effectiveness of Pegcetacoplan Compared with Ravulizumab for Treatment of Paroxysmal Nocturnal Haemoglobinuria - Supplementary materials.docx

Download (30.83 kB)
posted on 2022-07-07, 08:35 authored by Zalmai Hakimi, Koo Wilson, Eoin McAughey, Michal Pochopien, Piotr Wojciechowski, Mondher Toumi, Chris KnightChris Knight, Sujata P. Sarda, Nikita Patel, Catherine Wiseman, Nuno Pinto de Castro, Jameel Nazir, Richard J Kelly


Supplementary Table 1. Estimated utilities based on the Longworth and McKenzie algorithms 


Supplementary Table 2. Key scenario analyses


Supplementary Table 3. Probability of developing adverse events per cycle 


Supplementary Table 4. Iron overload disutility


Supplementary Table 5. Number of physician visits/tests per cycle1 and unit healthcare costs


Supplementary Table 6. Ravulizumab iron chelation costs


Supplementary Table 7. Intravascular haemolysis breakthrough cost for patients who discontinue pegcetacoplan due to intravascular haemolysis breakthrough


Supplementary Table 8. Unit costs of managing adverse events


Supplementary Table 9. OWSA results for the 10 parameters that contribute the largest difference to the NMB for pegcetacoplan versus ravulizumab 


Swedish Orphan Biovitrum AB, (Grant / Award Number)